He s the first patient outside of a clinical trial to start a new genetic treatment that was shown in clinical trials to cure 88% of people of the hallmark symptoms of sickle cell disease.
Matthew Frank, MD, PhD, discusses findings from prior research investigating a CD22-directed CAR T-cell therapy that informed the rationale for launching a phase 1 trial with this agent in patients with relapsed/refractory large B-cell lymphoma.